|
|
 |
|
Viewing report
|
|
|
|
Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
Bioseeker, April 2009, Pages: 512
This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:
- Providing competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing commercial analytic support for due diligence on in-licensing and acquisition opportunities
This report will also be an important part of creating and implementing a market development plan for any leukemia drugs to ensure that the optimal market conditions exist by the time the product is commercialized.
Our leukemia pipeline evaluation of development options, competitive landscape and positioning is derived through extensive pipeline benchmarking analysis, including:
Single Drug Target Analysis of 136 Drug Targets
- Highlighting twelve themes about the drug target (i.e. Drugs and investigators sharing a particular target, Types of compounds aimed at a specific target, Protein-protein interactions of a specific target with other known leukemia drug targets, Pathway involvement of a drug target, Presence of structural and protein expression data of a target etc.)
- Supportive chapters on selected drug themes above
Competitive Landscape Analysis based on 115 Identified Drug Target Combinations
- Identifies New and Unique leukemia drugs by developmental stage
- Head-to-head targeting competition
- Targeting competition by at least 50% bi-directional drug target combination match
- Clinical validation and progress on all identified drug target combinations
Competitive Landscape Analysis based on Compound Strategies at Work
- Identifies New and Unique leukemia drugs based on six different compound strategies (Small molecules, Peptide/Protein, Antibody, Nucleic acid therapies, Gene therapy and Re-formulation drugs)
- Head-to-head targeting competition
- Targeting competition by at least 50% bi-directional drug target combination match
Competitive Benchmarking of Leukemia Pipeline by 126 Investigators
- Competitive Fall-out table for each of the included investigators’ leukemia pipeline, overlaid with head-to-head targeting competitors’ drugs
- Competitive summary profile for each one of the 175 included leukemia drugs
Customers who bought this item also bought
Leukemia-Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
|
|
|
|
